BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18347560)

  • 1. Controversies regarding the use of dexamethasone in patients with multiple myeloma.
    Rajkumar SV
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):103, 141. PubMed ID: 18347560
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New treatment strategies for multiple myeloma].
    Ozaki S
    Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
    [No Abstract]   [Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
    Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
    Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
    [No Abstract]   [Full Text] [Related]  

  • 5. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
    Richardson P; Anderson K
    J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
    [No Abstract]   [Full Text] [Related]  

  • 6. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
    Hornberger J; Rickert J; Dhawan R; Liwing J; Aschan J; Löthgren M
    Eur J Haematol; 2010 Dec; 85(6):484-91. PubMed ID: 20846301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hematopoietic stem cell transplantation for multiple myeloma].
    Kanda Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1420-6. PubMed ID: 19915350
    [No Abstract]   [Full Text] [Related]  

  • 8. [Chemotherapy for multiple myeloma].
    Ishida T
    Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel agents in myeloma: an exciting saga.
    Mark T; Niesvizky R; Coleman M
    Cancer; 2009 Jan; 115(2):236-42. PubMed ID: 19025986
    [No Abstract]   [Full Text] [Related]  

  • 10. First-line treatment of elderly multiple myeloma patients.
    Palumbo A
    Clin Adv Hematol Oncol; 2010 Aug; 8(8):529-30. PubMed ID: 20966887
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
    Lemaire O; Attal M; Bourin P; Laroche M
    Eur J Haematol; 2010 Mar; 84(3):276-7. PubMed ID: 19891699
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment options for relapsed and refractory multiple myeloma.
    Lonial S; Mitsiades CS; Richardson PG
    Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Avvisati G
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090032
    [No Abstract]   [Full Text] [Related]  

  • 15. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
    Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
    Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract]   [Full Text] [Related]  

  • 17. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

  • 18. Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
    Chim CS; Choi PT; Lee WK
    Ann Hematol; 2013 Jun; 92(6):855-7. PubMed ID: 23183880
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens.
    Manier S; Barthelemy M; Fouquet G; Prod'homme C; Le Ray E; Samarcq P; Noel MP; Terriou L; Facon T; Cossment C; Boulanger F; Leleu X
    Leukemia; 2012 Dec; 26(12):2552-4. PubMed ID: 22627696
    [No Abstract]   [Full Text] [Related]  

  • 20. [Carfilzomib in multiple myeloma relapses].
    Bay JO
    Bull Cancer; 2015 Feb; 102(2):116. PubMed ID: 25874287
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.